Merck is investing in M&A activity to strengthen its pipeline. Merck boasts a strong cancer pipeline, including Keytruda, which should drive long-term growth. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.Īnimal health and vaccine products are core growth drivers. Company’s products like Keytruda and Gardasil have been driving sales. Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+33.7% vs. (You can read the full research report on UnitedHealth Group here >) As such, the stock warrants a cautious stance. High operating costs are hurting margins. However, the membership in its global business continues to decline. A sturdy balance sheet enables business investments and prudent deployment of capital. The Government business remains well-poised for growth. UnitedHealth Group’s solid health services segment provides diversification benefits. The company’s top line remains well-poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. Shares of UnitedHealth Group have gained +3.8% over the past year against the Zacks Medical - HMOs industry’s gain of +5.7%. You can see all of today’s research reports here > These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. The Zacks Research Daily presents the best research output of our analyst team. Today's Must Read Solid Top Line & Strong Cash Flows Drive UnitedHealth (UNH) Keytruda to Remain Merck's (MRK) Key Top Line Driver Embedded Processing Strength Aids Texas Instruments (TXN)
0 Comments
Leave a Reply. |